Type 5 Phosphodiesterase Inhibitors in Treatment of Patients with Hyperactive Bladder
Objective: comparative assessment of type 5 phosphodiesterase inhibitors (Vardenafil) and M-cholinolytic (Solifenacin) efficiency in treatment of patients with hyperactive bladder. Materials and methods: 26 males (group 1) with urodynamically confirmed hyperactive bladder and erectile dysfunction complaints took 10 mg of vardenafil twice a day for 8 weeks. 26 males in control group took 5 mg of solifenacin a day for 8 weeks. Treatment efficiency was evaluated due to visual analog scale, I-PSS score, Homma scale, urinary diary and, in first group, urodynamic assessments.
- Read more about Type 5 Phosphodiesterase Inhibitors in Treatment of Patients with Hyperactive Bladder
- Log in or register to post comments
- 21345 views